Welcome to our dedicated page for Interpace Biosciences SEC filings (Ticker: IDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpace Biosciences’ disclosures can run hundreds of pages—dense with genomic terminology, CLIA requirements and reimbursement risk factors that few investors have time to decode. If you have ever searched for “Interpace Biosciences SEC filings explained simply”, you already know the challenge.
Stock Titan solves it with AI-powered summaries that translate every filing into plain English within minutes of its appearance on EDGAR. Whether you need the full Interpace Biosciences annual report 10-K simplified for market sizing, the latest Interpace Biosciences quarterly earnings report 10-Q filing to check cash burn, or Interpace Biosciences 8-K material events explained after a new assay launch, our platform delivers real-time clarity. We also surface Interpace Biosciences Form 4 insider transactions real-time so you can monitor executive confidence, complete with alerts that flag any significant Interpace Biosciences executive stock transactions Form 4.
Beyond speed, you’ll gain context. Our expert analysis links laboratory certifications, payer-mix disclosures and intellectual-property updates directly to valuation drivers. Quickly answer questions like “How is revenue distributed across thyroid vs. pancreatic assays?” or dive into the Interpace Biosciences proxy statement executive compensation to see how management incentives align with assay adoption. Need a deeper dive? The “Ask AI” tool lets you type “understanding Interpace Biosciences SEC documents with AI” and receive instant explanations. Investors tracking catalysts appreciate the side-by-side view that pairs financial metrics with Interpace Biosciences earnings report filing analysis and historical trend charts. Every form—10-K, 10-Q, 8-K, S-3, DEF 14A—arrives the second it’s filed, giving you the confidence to act on Interpace Biosciences insider trading Form 4 transactions or any other disclosure without wading through jargon.
Interpace Biosciences, Inc. (IDXG) furnished an 8-K under Item 2.02 announcing results of operations and financial condition for the quarter ended September 30, 2025. The company issued a press release, included as Exhibit 99.1, providing the full details.
The information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
Interpace Biosciences (IDXG) reported Q3 results. Revenue was $8.756 million, down 29% from $12.295 million a year ago, reflecting the April 2025 loss of Medicare coverage for PancraGEN. Gross profit was $5.439 million. Operating income from continuing operations was $1.145 million versus $2.301 million, and net income was $0.911 million versus $1.676 million.
For the nine months, revenue was $29.504 million, down from $34.515 million; operating income was $2.507 million versus $6.047 million; net income was $1.918 million versus $4.821 million. The company recorded $0.7 million in severance and related costs tied to its restructuring plan. Cash and cash equivalents were $1.423 million as of September 30, 2025, with current assets of $9.130 million and current liabilities of $5.945 million. The BroadOak term loan balance was $1.0 million (fair value $0.977 million) with the maturity extended to December 31, 2025 and interest-only payments beginning July 1, 2025. Shares outstanding were 4,428,539 as of November 7, 2025.
Adjusted EBITDA was $1.263 million in Q3 and $3.735 million year-to-date. Management notes continued focus on cost controls, receivable collections, and financing or strategic alternatives following the PancraGEN coverage change.
FAQ
What is the current stock price of Interpace Biosciences (IDXG)?
What is the market cap of Interpace Biosciences (IDXG)?
